https://www.cphi.cn 2018-08-02 13:48 来源：药明康德
结果显示，200mg或400mg的sotagliflozin与耐受剂量的胰岛素疗法都显示出A1C水平和体重的统计学显著降低。与安慰剂相比，使用sotagliflozin 400mg观察到较低的严重低血糖发生率。并且还观察到某些血糖控制元素的改善，包括空腹血糖（FPG）和血糖变化等等。
参考资料
[1] Depleting microbiome with antibiotics can affect glucose metabolism
[2] Janssen Halts Phase III Kidney Disease Trial Early after Endpoints Were Met
[3] UAB researchers cure type 2 diabetes and obesity in mice using gene therapy
[4] Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3
[5] Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
原标题：盘点 | 糖尿病研究领域近期进展汇总（第59期）
如果这篇文章侵犯了您的权利，请联系我们。
投稿合作联系方式： Kelly.Xiao@imsinoexpo.com 021-33392297
地址：上海市徐汇区虹桥路355号城开国际大厦7-8楼 200030
